Journal
NATURE REVIEWS IMMUNOLOGY
Volume 18, Issue 11, Pages 671-688Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41577-018-0061-z
Keywords
-
Categories
Funding
- European Research Council (ERC) under the European Union Horizon 2020 research and innovation programme (Targeting innate lymphoid cells (TILC)) [694502]
- Agence Nationale de la Recherche
- Ministere de l'Enseignement Superieur, de la Recherche et de l'Innovation
- Ligue Nationale contre le Cancer
- MSDAvenir
- Innate Pharma
- Equipe Labellisee La Ligue
Ask authors/readers for more resources
Immuno-oncology is an emerging field that has revolutionized cancer treatment. Most immunomodulatory strategies focus on enhancing T cell responses, but there has been a recent surge of interest in harnessing the relatively underexplored natural killer (NK) cell compartment for therapeutic interventions. NK cells show cytotoxic activity against diverse tumour cell types, and some of the clinical approaches originally developed to increase T cell cytotoxicity may also activate NK cells. Moreover, increasing numbers of studies have identified novel methods for increasing NK cell antitumour immunity and expanding NK cell populations ex vivo, thereby paving the way for a new generation of anticancer immunotherapies. The role of other innate lymphoid cells (group 1 innate lymphoid cell (ILC1), ILC2 and ILC3 subsets) in tumours is also being actively explored. This Review provides an overview of the field and summarizes current immunotherapeutic approaches for solid tumours and haematological malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available